Trial Profile
ONO-4538 Multicenter, Open-label, Uncontrolled, Phase II Study in Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 19 Mar 2021 Status changed from active, no longer recruiting to completed.
- 18 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.